232 related articles for article (PubMed ID: 8435987)
1. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.
Fukase N; Igarashi M; Takahashi H; Manaka H; Yamatani K; Daimon M; Tominaga M; Sasaki H
Diabet Med; 1993; 10(1):44-9. PubMed ID: 8435987
[TBL] [Abstract][Full Text] [Related]
2. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.
Fukase N; Manaka H; Sugiyama K; Takahashi H; Igarashi M; Daimon M; Yamatani K; Tominaga M; Sasaki H
Acta Diabetol; 1995 Oct; 32(3):165-9. PubMed ID: 8590785
[TBL] [Abstract][Full Text] [Related]
3. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
4. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion.
Fukase N; Takahashi H; Manaka H; Igarashi M; Yamatani K; Daimon M; Sugiyama K; Tominaga M; Sasaki H
Diabetes Res Clin Pract; 1992 Mar; 15(3):187-95. PubMed ID: 1576919
[TBL] [Abstract][Full Text] [Related]
5. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
6. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
[TBL] [Abstract][Full Text] [Related]
7. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
8. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.
Dirksen C; Bojsen-Møller KN; Jørgensen NB; Jacobsen SH; Kristiansen VB; Naver LS; Hansen DL; Worm D; Holst JJ; Madsbad S
Diabetologia; 2013 Dec; 56(12):2679-87. PubMed ID: 24048673
[TBL] [Abstract][Full Text] [Related]
9. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
[TBL] [Abstract][Full Text] [Related]
10. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction.
Verdich C; Toubro S; Buemann B; Lysgård Madsen J; Juul Holst J; Astrup A
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1206-14. PubMed ID: 11477506
[TBL] [Abstract][Full Text] [Related]
11. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
Greenfield JR; Farooqi IS; Keogh JM; Henning E; Habib AM; Blackwood A; Reimann F; Holst JJ; Gribble FM
Am J Clin Nutr; 2009 Jan; 89(1):106-113. PubMed ID: 19056578
[TBL] [Abstract][Full Text] [Related]
12. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
13. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
Holst JJ
BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
[TBL] [Abstract][Full Text] [Related]
14. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
Nauck MA; Siemsglüss J; Orskov C; Holst JJ
Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.
Ranganath L; Norris F; Morgan L; Wright J; Marks V
Clin Sci (Lond); 1999 Apr; 96(4):335-42. PubMed ID: 10087239
[TBL] [Abstract][Full Text] [Related]
16. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
17. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
[TBL] [Abstract][Full Text] [Related]
18. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
[TBL] [Abstract][Full Text] [Related]
19. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
20. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H
Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
